A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer

NCT ID: NCT06521567

Last Updated: 2025-11-12

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 83 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-03-06
• Study Completion Date: 2026-10-13

Brief Summary

The goal of this interventional study is to determine the strength of cobolimab and dostarlimab that is most tolerated in children and young adults who have advanced solid tumors. This study also aims: (a) to check if it is safe to use cobolimab and dostarlimab combination in children and young adults, (b) to see how to manage the side effects that may occur, and (c) the effect of this treatment in participants

Conditions

Melanoma; Hodgkin Lymphoma; High and Low Grade Glioma; Glioblastoma Multiforme (GBM); Diffuse Intrinsic Pontine Glioma (DIPG); Ependymoma; Osteosarcoma; Hepatic Tumors; Hepatoblastoma; Hepatocellular Carcinoma (HCC); Fibrolamellar Carcinoma; Rhabdomyosarcoma

Keywords

Solid Tumours; Cobolimab; Dostarlimab

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Part 1- Dose determination

Group Type: EXPERIMENTAL

Cobolimab

Intervention Type: DRUG

Cobolimab will be administered

Dostarlimab

Intervention Type: DRUG

Dostarlimab will be administered

Part 2- Dose expansion

Group Type: EXPERIMENTAL

Cobolimab

Intervention Type: DRUG

Cobolimab will be administered

Dostarlimab

Intervention Type: DRUG

Dostarlimab will be administered

Interventions

Cobolimab

Cobolimab will be administered

Intervention Type: DRUG

Dostarlimab

Dostarlimab will be administered

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

Participants are eligible to be included in the study only if all of the following criteria apply:

• Participants between the age of 0 to not more than 21 years at the time of signing informed consent form (ICF).
• Disease characteristics:

Part 1: Participants with advanced or metastatic solid tumors who have had disease progression after treatment with available therapies that are known to confer clinical benefit and who have limited available treatment options as determined by the investigator. Additionally, exposure to prior immunotherapy or experimental therapies is acceptable:

1. Melanoma

2. Hodgkin Lymphoma

3. High and Low Grade Glioma: including Glioblastoma multiforme (GBM), Diffuse intrinsic pontine glioma (DIPG), and ependymoma.

4. Osteosarcoma

5. Hepatic tumors [including Hepatoblastoma, Hepatocellular carcinoma (HCC), and Fibrolamellar carcinoma]

6. Rhabdomyosarcoma

Part 2:

1. Participants with Melanoma who have not received prior systemic therapy:

• Participants with BRAF gene, found on chromosome 7 (BRAF) mutations who are eligible for a BRAF-targeted therapy are eligible if they qualify for immunotherapy.
• Participants with locally treated and controlled metastatic central nervous system (CNS) lesions without leptomeningeal spread are eligible

2. Relapsed/refractory Hodgkin lymphoma (HL) that has failed at least 2 prior lines of systemic therapy)

• Participants must have performance status >=60 percent (%) on the Karnofsky scale for participants >16 years of age and >=60% on the Lansky scale for participants <=16 years of age.
• Adequate organ function as demonstrated by a complete blood count at screening obtained without transfusion [platelets or red blood cells (RBC)] or receipt of Colony stimulating factor (CSF), Granulocyte colony stimulating factor (G-CSF), Granulocyte macrophage colony stimulating factor (GMCSF) or rErythropoeitin (rEPO) within 2 weeks prior to screening.
• Adolescent participants who have entered puberty must consent (be willing) to use of contraceptive measures, or refrain from sexual intercourse, if in line with their usual practice, as well as sperm/egg donation for the duration of treatment

Exclusion Criteria

Participants are excluded from the study if any of the following criteria apply:

Medical conditions:

• Participant has uncontrolled CNS involvement by any tumor pathology
• Participant has a heart rate-corrected QT interval according to QT interval (corrected) (Friderecia's formula) (QTcF) prolongation at screening >470 millisecond (msec) or >480 msec for participants with bundle branch block.
• Participant has clinically significant cardiovascular disease
• Participant has chronic respiratory disease
• Participant has known sensitivity to study intervention components or excipients or other allergy that, in the opinion of the investigator or medical monitor, contraindicates participation in the study.
• Participants who have a history of immunodeficiency disease, including other acquired or congenital immunodeficiency diseases, or organ transplantation
• Participants who have received plasma exchange within 7 days before the first dose of study intervention.
• Participant has current active pneumonitis or any history of pneumonitis requiring steroids or immunomodulatory treatment within 90 days of planned enrollment or any history of drug-induced pneumonitis.
• Participant has a history of autoimmune disease that has required systemic treatments in the 2 years prior to screening. Participants with prior history of autoimmune disease must be discussed with the medical monitor. Replacement therapy is not considered a form of systemic therapy (e.g., thyroid hormone for autoimmune thyroiditis or insulin is not exclusionary)
• Participant has ongoing adverse reaction(s) from prior therapy that has (have) not recovered to ≤Grade 1 or to the Baseline status preceding prior therapy, excluding [e.g., alopecia, hearing loss, vitiligo, endocrinopathy managed with replacement therapy, and Grade 2 neuropathy], or that the investigator, with the agreement of the sponsor, considers to be not clinically relevant for the tolerability of study intervention in the current clinical study.
• Participant has any active renal condition (e.g., infection, requirement for dialysis, or any other significant renal condition (that could affect the participant's safety).
• Participant has any serious and/or unstable medical or psychiatric disorder or other condition(s) (including laboratory assessment abnormalities) that could interfere with the participant's safety, obtainment of informed consent, or compliance to the study procedures.

Prior/ Concomitant therapy:

• Has received treatment with an investigational agent or any other anti-cancer therapy within 30 days, or <5 times the half-life of the most recent therapy prior to signing ICF, whichever is shorter.
• Has received systemic steroid therapy within 3 days prior to the first dose of the study treatment or is receiving any other form of immunosuppressive medication. Replacement therapy is not considered a form of systemic therapy. Use of inhaled corticosteroids, local steroid injection, or steroid eye drops is allowed.
• Has not met the following waiting/washout periods for X-ray therapy (XRT) including external beam radiation therapy/external beam irradiation including protons:
• Participant has had major surgery within 28 days prior to the first dose of study treatment or has not adequately recovered from any AEs (Grade ≤1) and/or complications from any major surgery. Surgical implantation of a port catheter is not exclusionary.
• Prior Bone Marrow Transplant <60 days of screening.
• Participant has experienced Grade 3 or higher hypersensitivity to prior monoclonal antibody therapy.

Prior/Concurrent clinical study experience

• Is currently enrolled or has participated in any other clinical study involving an investigational study or interventional medical research within 21 days or 5 half-lives, whichever is shorter, of an investigational medicinal product before signing ICF Diagnostic assessments
• Has documented presence of Hepatitis B surface antigen (HbsAg) at Screening or within 3 months prior to first dose of study intervention.
• Has a positive Hepatitis C virus (HCV) antibody test result at Screening or within 3 months prior to first dose of study intervention.
• Has a positive HCV Ribonucleic Acid (RNA) test result at Screening or within 3 months prior to first dose of study intervention.
• Has a known history of Human immunodeficiency virus (HIV) or has a HIV-positive test result at Screening.
• Is pregnant or breastfeeding.

• Minimum Eligible Age: 0 Years
• Maximum Eligible Age: 21 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

GlaxoSmithKline

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

GSK Clinical Trials

Role: STUDY_DIRECTOR

GlaxoSmithKline

Locations

GSK Investigational Site

Los Angeles, California, United States

GSK Investigational Site

Iowa City, Iowa, United States

GSK Investigational Site

Hackensack, New Jersey, United States

GSK Investigational Site

Cincinnati, Ohio, United States

GSK Investigational Site

Providence, Rhode Island, United States

GSK Investigational Site

Madison, Wisconsin, United States

GSK Investigational Site

Brno, , Czechia

GSK Investigational Site

Phaha 5, , Czechia

GSK Investigational Site

Copenhagen, , Denmark

GSK Investigational Site

Bordeaux, , France

GSK Investigational Site

Lyon, , France

GSK Investigational Site

Paris, , France

GSK Investigational Site

Strasbourg, , France

GSK Investigational Site

Villejuif, , France

GSK Investigational Site

Bologna, , Italy

GSK Investigational Site

Napoli, , Italy

GSK Investigational Site

Barcelona, , Spain

GSK Investigational Site

Madrid, , Spain

GSK Investigational Site

Madrid, , Spain

GSK Investigational Site

Valencia, , Spain

Countries

Argentina; Brazil; Germany; South Korea; United States; Czechia; Denmark; France; Italy; Spain

Other Identifiers

2024-511350-41-00

Identifier Type: OTHER

Identifier Source: secondary_id

219451

Identifier Type: -

Identifier Source: org_study_id